Skip to content
DataLookout
Menu

MIRELANCT07896421

Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer

StatusRecruiting
PhaseNot specified
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Treatment Duration of MIRV Among Participants With Platinum-Resistant FRα-Positive Ovarian Cancer
Timeframe: Up to approximately 18 months

Arms and interventions

Mirvetuximab Soravtansine (MIRV)

Participants with FRα positive platinum-resistant ovarian, primary peritoneal or fallopian tube cancer and are scheduled to receive treatment with MIRV in accordance with the local label of the participating country.

Sites

1 site in 1 country

  • Medizinische Universitaet Wien /ID# 282657Vienna, Austria